Quotables
"Telephone, n. An invention of the devil which abrogates some of the advantages of making a disagreeable person keep his distance. "
Ambose Bierce
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 6852708 | Use of hyaluronic acid and forms to prevent the narrowing of the vascular walls For the prevention of the narrowing of the tubular walls of an animal after the tubular walls have been traumatized, the administration of a therapeutically effective non-toxic amount of a form of Hyaluronic Acid selected from Hyaluronic Acid, salts thereof and comb... | 02/08/2005 |
| 6838448 | Corneal storage fluid comprised of hyaluronic acid A solution for storing corneal tissue, especially at a temperature of 2 to 8° C., which comprises hyaluronic acid having an average molecular weight of less than 6,000,000 Da (preferably of from 50,000 to 250,000 Da). ... | 01/04/2005 |
| 6770672 | Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof The present invention provides an antiproliferative compound having the structural formula wherein X is oxygen, nitrogen or sulfur; Y is selected from the group consisting of oxygen, nitrogen and sulfur wherein when Y is... | 08/03/2004 |
| 6756208 | Plasma glucosylceramide deficiency as risk factor for thrombosis and modulator of anticoagulant protein C The present invention has determined that exogenously added glycosylceramide (GlcCer) and other neutral glycolipids such as the homologous Glc-containing globotriaosylceramide (Gb3Cer), dose-dependently prolonged clotting times of normal plasma in the presence but n... | 06/29/2004 |
| 6743783 | Pharmaceutical compositions comprising poly-β-1→4-N-acetylglucosamine The present invention relates to a purified, easily produced poly-β-1→4-N-acetylglucosamine (p-GlcNAc) polysaccharide species. The p-GlcNAc of the invention is a polymer of high molecular weight whose constituent monosaccharide sugars are attached in a β-1→4 c... | 06/01/2004 |
| RE38520 | Erythromycin derivatives, method for preparing same, and use thereof as drugs A subject of the invention is the compounds of formula (I): in which: X represents a CH2 or SO2 radical or an oxygen atom, Y represents a (CH2)m—(CH═CH)n(CH2 | 05/18/2004 |
| 6703377 | Method of promoting bone growth with hyaluronic acid and growth factors A bone growth-promoting composition is provided comprising hyaluronic acid and a growth factor. The composition has a viscosity and biodegradability sufficient to persist at an intra-articular site of desired bone growth for a period of time sufficient to... | 03/09/2004 |
| 6689763 | Antibiotics AA-896 This invention relates to new antibiotics designated AA-896-A1, AA-896-A2, AA-896-A3, AA-896-A4, AA-896-A5, AA-896-A6, AA-896-B1, AA-896-B2, AA-896-B3, AA-896-B4, AA-896-B5, AA-896-B6, AA-896-B7, AA-896-C1, AA-896-C2, AA-896-C3, AA-896-C4, AA-896-C5, AA-8... | 02/10/2004 |
| 6686342 | Bicompatible poly-ଲ-1.fwdarw.4-N-acetylglucosamine The present invention relates to a purified, easily produced poly-ଲ-1.fwdarw.4-N-acetylglucosamine (p-GlcNAc) polysaccharide species. The p-GlcNAc of the invention is a polymer of high molecular weight whose constituent monosaccharide sugars are att... | 02/03/2004 |
| 6683064 | Cross-linked polysaccharide drug carrier A carrier and a method for preparing it are provided for use in the delivery of therapeutic agents. A polysaccharide is reacted with an oxidizing agent to open sugar rings on the polysaccharide to form aldehyde groups. The aldehyde groups are reacted to f... | 01/27/2004 |
| 6683056 | O-aryl glucoside SGLT2 inhibitors and method ##STR1## wherein when Y is ##STR2## or heteroaryl; A is --O(CH2)m, S, --NH(CH2)m, or (CH2)n where n is 0-3 and m is 0-2; and R1 to R6 are as defined herein... | 01/27/2004 |
| 6680339 | 15-fluoro prostaglandins as ocular hypotensives 15-fluoro substituted analogs of PGF2 and methods of their use in treating glaucoma and ocular hypertension are disclosed.... | 01/20/2004 |
| 6680306 | Method for enhancing the effectiveness of cancer therapies The efficacy of conventional cancer therapies such as surgery, chemotherapy and radiation is enhanced by the use of a therapeutic material which binds to and interacts with galectins. The therapeutic material can enhance apoptosis thereby increasing the e... | 01/20/2004 |
| 6680340 | Anti-hypercholesterolemic drug combination This invention provides a drug combination comprised of a thyroid hormone receptor beta agonist with a fibrate in therapeutically effective amounts, which is useful for reducing cholesterol synthesis, lowering plasma cholesterol levels and lowering plasma... | 01/20/2004 |
| 6670340 | 6-Mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block Disclosed is a 6-mercapto-cyclodextrin derivative having general formula (I) wherein m is 0-7 and n is 1-8 and m+n=7 or 8; R is (C1-6)alkylene, optionally substituated with 1-3 OH groups, or (CH2)o -phenylene-(CH2 | 12/30/2003 |
| 6667296 | Method for preventing and reducing radiation cystitis using hyaluronic acid A method for preventing, reducing or treating radiation cystitis caused by external beam radiation therapy, which impinges on the urinary bladder and associated structures, comprising administering into the urinary bladder and associated structures a comp... | 12/23/2003 |
| 6664243 | Benzyllactobionamides as inhibitors of smooth muscle cell proliferation This invention provides smooth muscle cell proliferation inhibitors of formula I having the structure ##STR1## wherein R1 -R13 are as defined herein.... | 12/16/2003 |
| 6656923 | Uncomplexed cyclodextrin compositions for odor and wrinkle control The present invention relates to a stable, aqueous odor-absorbing and wrinkle controlling composition, preferably for use on inanimate surfaces, especially fabrics. The composition comprises from about 0.1% to about 20%, by weight of the composition, of s... | 12/02/2003 |
| 6653294 | Use of chitinous materials for inhibiting cellular nitric oxide production The invention relates to a method of reducing nitric oxide production by a cell in vitro or in a mammal by a cell by contacting the cell with chitosan or its derivatives in an amount effective to reduce nitric oxide production in the cell.... | 11/25/2003 |
| 6653456 | Site-specific aminoglycoside derivatives and their use in immunodiagnostic assays A method of making a derivatized aminoglycoside includes reacting an aminoglycoside with at least 2 equivalents of a divalent metal ion in an aprotic solvent to complex two neighboring amino group and hydroxyl group pairs; reacting the non-complexed amino... | 11/25/2003 |
| 6649599 | Methods and compositions for poly-ଲ-1-4-N-acetylglucosamine cell therapy system The present invention relates to a purified, easily produced poly-ଲ-1.fwdarw.4-N-acetylglucosamine (p-GlcNAc) polysaccharide species. The p-GlcNAc of the invention is a polymer of high molecular weight whose constituent monosaccharide sugars are att... | 11/18/2003 |
| 6649653 | 15-fluoro prostaglandins as ocular hypotensives 15-Fluoro substituted analogs of PGF2 and methods of their use in treating glaucoma and ocular hypertension are disclosed.... | 11/18/2003 |
| 6645940 | Oligosaccharide derivatives and process for producing the same An oligosaccharide derivative, at higher homogeneity than fucose polysaccharide and rhamnose polysaccharide and with greater antiulcer effects, which is represented by the following general formula: wherein, Y represents an oligofucose or oligorhamnose at a po... | 11/11/2003 |
| 6645945 | Method of treating diseased, injured or abnormal cartilage with hyaluronic acid and growth factors A composition is provided for treating diseased, injured or diseased cartilage comprising hyaluronic acid and a growth factor. The composition has a viscosity and biodegradability sufficient to persist at the site for a period of time sufficient to allevi... | 11/11/2003 |
| 6645998 | Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof The present invention provides an antiproliferative compound having the structural formula ##STR1## wherein X is oxygen, nitrogen or sulfur; R1 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, carboxylic acid, carboxylate, carboxamide, ester,... | 11/11/2003 |
| 6645935 | Synthesis of glycoconjugates of the lewis Y epitope and uses thereof The present invention provides a method of synthesizing an allyl pentasaccharide having the structure: ##STR1## as well as related oligosaccharide ceramides and other glycoconjugates useful as vaccines for inducing antibodies to epithelial cancer cells in... | 11/11/2003 |
| 6639105 | Illudin analogs useful as antitumor agents The present invention provides illudin analogs of the general formula (I): ##STR1## where R1 is (CH2)n --X--Y or H; n is 0 to 4; X is O or S or N or absent; and Y is an optionally substituted (C1 -C8)alkyl... | 10/28/2003 |
| 6635622 | Glycolipid derivative The present invention is a compound of general formula (I) or a pharmaceutically acceptable salt of, ##STR1## wherein W represents carbon chain from 9 to 17 which containing double bond or hydroxy group occasionally; X represents carbon chain from 11 to 2... | 10/21/2003 |
| 6632804 | Compositions useful in the treatment of diseases of connective tissues Compositions comprising ferrous ion and an ascorbate have a synergistic effect on cartilage development. Therapeutic compositions comprising ferrous ion and an ascorbate are therefore useful in the treatment of osteoarthritis. The addition of a glucosamin... | 10/14/2003 |
| 6632939 | Process for producing dextran reduced in boron content The present invention relates to dextran whose boron content is reduced to a value less than 0.30 μg/g (dry basis) calculated on the basis of boron atom, a process for producing the same, and dextran with which a container is filled in a solution state. ... | 10/14/2003 |
| 6632796 | Pharmaceutical compositions for promoting the growth of gram-positive bacilli and increasing the acidity in vagina and the use thereof The present invention relates to a pharmaceutical formulation for stimulating the growth of gram-positive bacilli and increasing the acidity in the vagina which comprises sucrose and/or maltose, to the use of certain sucrose and/or maltose, in preparing t... | 10/14/2003 |
| 6632803 | Pharmaceutical formulations containing voriconazole The invention provides pharmaceutical formulation comprising voriconazole, or a pharmaceutically acceptable derivative thereof, and a sulfobutylether ଲ-cyclodextrin.... | 10/14/2003 |
| 6632801 | Method and composition for inhibiting human cholesterol esterase A method and composition for inhibiting human cholesterol absorption comprising ingesting a therapeutic amount of an inhibitor of human cholesterol esterase comprising very high molecular weight sulfated polysaccharide having a sulfate to monomer ratio of... | 10/14/2003 |
| 6632802 | Hyaluronic acid esters, threads and biomaterials containing them, and their use in surgery The application discloses esters of hyaluronic acid, wherein a first part of the carboxylic functions is esterified with an araliphatic alcohol and a second part is esterified with at least one long-chain, straight aliphatic alcohol with between 10 and 22... | 10/14/2003 |
| 6630457 | Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same Methods for chemical modification of hyaluronic acid, formation of amine or aldehyde functionalized hyaluronic acid, and the cross-linking thereof to form hydrogels are provided. Functionalized hyaluronic acid hydrogels of this invention can be polymerize... | 10/07/2003 |
| 6630580 | Silyl and Heparin compositions The present invention provides an anti-thrombogenic and cellular-adhesion coating composition for blood-contacting surfaces. The coating comprises a covalent complex of from 1 to 30 hydrophobic silyl moieties of Formula I: ##STR1## wherein R1 i... | 10/07/2003 |
| 6630586 | Branched maltodextrins and method of preparing them The subject matter of the invention is branched maltodextrins, characterised by the fact that they present between 22% and 35%, preferably between 27 and 34%, glucosidic linkages 1.fwdarw.6, a content of reducing sugars lower than 20%, a polymolecularity ... | 10/07/2003 |
| 6630459 | Pharmaceutical compositions comprising poly-ଲ-1.fwdarw.4-N-acetylglucosamine The present invention relates to a purified, easily produced poly-ଲ-1.fwdarw.4-N-acetylglucosamine (p-GlcNAc) polysaccharide species. The p-GlcNAc of the invention is a polymer of high molecular weight whose constituent monosaccharide sugars are att... | 10/07/2003 |
| 6627621 | Neutrophil function inhibitors Glucosamine salts are effective for the inhibition of neutrophil functions, and hence, are useful for the prevention and/or treatment of diseases, caused as a result of an excessive extracellular release of active oxygen and antibiotic proteins by neutrop... | 09/30/2003 |
| 6627744 | Synthesis of glycodendrimer reagents The present invention relates to a chemically modified mutant protein including a cysteine residue substituted for a residue other than cysteine n a precursor protein, the substituted cysteine residue being subsequently modified by reacting the cysteine r... | 09/30/2003 |
